Joel H Vazquez
Overview
Explore the profile of Joel H Vazquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yiew N, Vazquez J, Martino M, Kennon-McGill S, Price J, Allard F, et al.
Mol Metab
. 2023 Sep;
77:101808.
PMID: 37716594
Objective: Mitochondrial pyruvate is a critical intermediary metabolite in gluconeogenesis, lipogenesis, and NADH production. As a result, the mitochondrial pyruvate carrier (MPC) complex has emerged as a promising therapeutic target...
2.
Vazquez J, Kennon-McGill S, Byrum S, Mackintosh S, Jaeschke H, Williams D, et al.
Toxicol Sci
. 2022 Feb;
187(1):25-34.
PMID: 35172013
Better biomarkers to predict death early in acute liver failure (ALF) are needed. To that end, we obtained early (study day 1) and later (day 3) serum samples from transplant-free...
3.
Clemens M, Kennon-McGill S, Vazquez J, Stephens O, Peterson E, Johann D, et al.
Acta Pharm Sin B
. 2022 Jan;
11(12):3836-3846.
PMID: 35024310
We previously demonstrated that endogenous phosphatidic acid (PA) promotes liver regeneration after acetaminophen (APAP) hepatotoxicity. Here, we hypothesized that exogenous PA is also beneficial. To test that, we treated mice...
4.
Vazquez J, McGill M
Livers
. 2021 Dec;
1(4):286-293.
PMID: 34966905
Circulating biomarkers of drug-induced liver injury (DILI) have been a focus of research in hepatology over the last decade, and several novel DILI biomarkers that hold promise for certain applications...
5.
McGill M, James L, McCullough S, Moran J, Mathews S, Peterson E, et al.
Hepatol Commun
. 2021 Sep;
6(2):361-373.
PMID: 34558847
Current guidelines recommend restricting acetaminophen (APAP) use in patients with cirrhosis, but evidence to support that recommendation is lacking. Prior studies focused on pharmacokinetics (PK) of APAP in cirrhosis but...
6.
Clemens M, Vazquez J, Kennon-McGill S, McCullough S, James L, McGill M
Liver Res
. 2020 Oct;
4(3):145-152.
PMID: 33042596
Background And Aim: Acetaminophen (APAP) overdose is a major cause of acute liver injury, but the role of macrophages in propagation of the hepatotoxicity is controversial. Early research revealed that...
7.
Vazquez J, Clemens M, Allard F, Yee E, Kennon-McGill S, Mackintosh S, et al.
Toxicol Sci
. 2019 Oct;
173(2):244-254.
PMID: 31651977
The standard circulating biomarker of liver injury in both clinical settings and drug safety testing is alanine aminotransferase (ALT). However, ALT elevations sometimes lack specificity for tissue damage. To identify...
8.
Ewing L, McGill M, Yee E, Quick C, Skinner C, Kennon-McGill S, et al.
Molecules
. 2019 Jun;
24(12).
PMID: 31212965
The goal of this study was to investigate the potential for a cannabidiol-rich cannabis extract (CRCE) to interact with the most common over-the-counter drug and the major known cause of...